ManagingMPN

Reference List

1. Schieber M, Crispino JD, Stein B. Myelofibrosis in 2019: Moving beyond JAK2 inhibition. *Blood Cancer J.* 2019;9:74.
2. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. *Leuk Lymphoma.* 2014;55:595-600.
3. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. *Leukemia.* 2014;28:1472-1477.
4. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. *Blood.* 2009;113:2895-2901.
5. Gangat N, Caramazza D, Vaidya R, et al. DIPSS Plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol.* 2011;29:392-397.
6. Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: Pathogenesis, clinical manifestations, and effects on outcomes. *Int J Gen Med.* 2017;7:89-101.
7. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. *Blood.* 2010;116:2857-2858.
8. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy. *Am J Hematol.* 2008;83:491-497.
9. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer J.* 2018;8:15.
10. Savona MR. Are we altering the natural history of primary myelofibrosis? *Leuk Res.* 2016;38:1004-1012.
11. Rumi E, Pietra D, Pascutto C, et al, for the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. *Blood.* 2014;124:1062-1069.
12. Vannuchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. *Leukemia.* 2013;27:1861-18619.
13. Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. *Am J Hematol.* 2014;89:915-925.
14. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. *Leukemia.* 2014;28:1804-1810.
15. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood*. 2010;115:1703-1708.
16. Hernández-Boluda JC, Pereira A, Correa G, et al. Prognostic risk models for transplant decision-making in myelofibrosis. *Ann Hematol.* 2018;97:813-820.
17. Vannucchi AM, Guglielmelli P, Rotunno G, et al. Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project. *Blood.* 2014;124:405.

18. Guglielmelli P, Lasho P, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. *J Clin Oncol.* 2018;36:310-318.
19. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myelodysplastic syndromes. Version 1.2020 – August 27, 2019. Available at: www.nccn.org. Accessed November 10, 2019.
20. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med.* 2012;366:799-807.
21. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *N Engl J Med.* 2012;366:787-798.
22. Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. *J Hematol Oncol.* 2017;10:156. Published online 2017 Sep 29. doi: 10.1186/s13045-017-0527-7.
23. Bryan JC, Verstovsek S. Overcoming treatment challenges in myelofibrosis and polycythemia vera: The role of ruxolitinib. *Cancer Chemother Pharmacol.* 2016;77:1125-1142.
24. Al-Ali HK, Griesshamer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: A snapshot of 1144 patients in the JUMP trial. *Haematologica*. 2016;101:1065-1073.
25. Mead AJ, Milojkovic D, Knapper S, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: Results of the UK ROBUST Trial. *Br J Haematol*. 2015;170:29-39.
26. Palandri F, Palumbo G, Bonifacio M, et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. *Leuk Res.* 2018;74:86-88.
27. Verstovsek S, Mesa R, Gotlib J, et al, for the COMFORT-I investigators. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: Results of a median 3-year follow-up of COMFORT-I. *Haematologica*. 2015;100:479-488.
28. Palandri F, Tiribelli M, Benevolo G, et al. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. *Hematol Oncol*. 2018;36:285-290.
29. Palandri F, Palumbo GA, Bonifacio M, et al. Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis. *Oncotarget.* 2017;8:79073-79086.
30. Menghrajani K, Boonstra PS, Mercer JA, et al. Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. *Leuk Lymphoma.* 2019;60:1036-1042.
31. Verstovsek S, Gotlib J, Gupta V, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. *Onco Targets Ther*. 2013;7:13-21.
32. Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. *Blood.* 2015;126:790-797.
33. Newberry KJ, Patel K, Masarove L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. *Blood.* 2017;130:1125-1131

34. Gerds A, Su D, Martynova A, et al. Ruxolitinib rechallenge can improve constitutional symptoms and splenomegaly in patients with myelofibrosis: A case series. *Clin Lymphoma Myeloma Leuk.* 2018;18:e463-e468.
35. Kuykendall AT, Shah S, Talati C, et al. Between a rux and a hard place: Evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. *Ann Hematol.* 2018;97:435-441.
36. Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. *JAMA Oncol*. 2015;1:643-651.
37. Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Haematol.* 2017;4:e317-e324.
38. Harrison CN, Schaap N, Vannuchi AM, et al. Fedratinib in patients with myeloproliferative neoplasm-associated myelofibrosis previously treated with ruxolitinib: A reanalysis of the JAKART2 study. EHA 2019. Abstract PS1459. https://library.ehaweb.org/eha/2019/24th/267076/claire.harrison.fedratinib.in.patients.with.myeloproliferative.neoplasm.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dmyelofibrosis
39. Harrison CN, Schaap N, Vannuchi AM, et al. Fedratinib induces spleen responses in patients with myeloproliferative neoplasm-associated intermediate- or high-risk myelofibrosis (MF) previously exposed to ruxolitinib (RUX), regardless of reason for discontinuing RUX. ASH 2019. Abstract 4165.
40. Mesa R, Schaap N, Vannuchi, AM, et al. Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study. ASH 2019. Abstract 704.
41. Harrison CN, Chaap N, Vannuchi AM, et al. Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. ASH 2019. Abstract 2207.